公开(公告)号：US06602977B1

公开(公告)日：2003-08-05

申请号：US09549441

申请日：2000-04-14

申请人： Charlotta Ljungqvist ,  Karin Nord ,  Per-Åke Nygren ,  Mathias Uhlén

发明人： Charlotta Ljungqvist ,  Karin Nord ,  Per-Åke Nygren ,  Mathias Uhlén

IPC分类号： A61K3800

CPC分类号： C07K14/31 ,  C12N15/1034

摘要： The present invention relates to modified polypeptide derivatives of the B domain or Z domain of staphylococcal protein A (SPA). The derivatives contain amino acid substitutions that result in the ability of the B domain or Z domain to interact with at least one domain of a human Factor VIII protein, without substantially disrupting the structure and stability of the B domain or Z domain.

摘要翻译： 本发明涉及葡萄球菌蛋白A（SPA）的B结构域或Z结构域的修饰多肽衍生物。 衍生物含有导致B结构域或Z结构域与人因子VIII蛋白的至少一个结构域相互作用的能力的氨基酸取代，而基本上不破坏B结构域或Z结构域的结构和稳定性。

公开(公告)号：US06740734B1

公开(公告)日：2004-05-25

申请号：US09568051

申请日：2000-05-10

申请人： Björn Nilsson ,  Per-Åke Nygren ,  Mathias Uhlén

发明人： Björn Nilsson ,  Per-Åke Nygren ,  Mathias Uhlén

IPC分类号： C07K100

CPC分类号： C07K14/315 ,  C07K14/31 ,  C07K2319/00

摘要： Novel proteins obtainable by mutagenesis of surface-exposed amino acids of domains of natural bacterial receptors, said proteins being obtained without substantial loss of basic structure and stability of said natural bacterial receptors; proteins which have been selected from a protein library embodying a repertoire of said novel proteins; and methods for the manufacture of artificial bacterial receptor structures.

摘要翻译： 可通过诱变天然细菌受体结构域的表面暴露氨基酸获得的新型蛋白质，所述蛋白质获得而不显着损失所述天然细菌受体的碱性结构和稳定性; 选自蛋白质文库的蛋白质，其中包含所述新蛋白质的所有组成成分; 以及用于制造人造细菌受体结构的方法。

公开(公告)号：US06534628B1

公开(公告)日：2003-03-18

申请号：US09082468

申请日：1998-05-21

申请人： Björn Nilsson ,  Per-Åke Nygren ,  Mathias Uhlén

发明人： Björn Nilsson ,  Per-Åke Nygren ,  Mathias Uhlén

IPC分类号： C07K100

CPC分类号： C12N15/1037 ,  C07K14/31 ,  C07K14/315 ,  C07K2319/00 ,  Y10S435/882 ,  Y10S435/883 ,  Y10S530/825

摘要： Novel proteins obtainable by mutagenesis of surface-exposed amino acids of domains of natural bacterial receptors, said proteins being obtained without substantial loss of basic structure and stability of said natural bacterial receptors; proteins which have been selected from a protein library embodying a repertoire of said novel proteins; and methods for the manufacture of artificial bacterial receptor structures.

摘要翻译： 可通过诱变天然细菌受体结构域的表面暴露氨基酸获得的新型蛋白质，所述蛋白质获得而不显着损失所述天然细菌受体的碱性结构和稳定性; 选自蛋白质文库的蛋白质，其中包含所述新蛋白质的所有组成成分; 以及用于制造人造细菌受体结构的方法。

公开(公告)号：US06267964B1

公开(公告)日：2001-07-31

申请号：US08162906

申请日：1993-12-08

申请人： Per Åke Nygren ,  Hans Wigzell ,  Mathias Uhlén

发明人： Per Åke Nygren ,  Hans Wigzell ,  Mathias Uhlén

IPC分类号： A61K3900

CPC分类号： C07K14/315 ,  A61K38/00 ,  A61K47/646 ,  C07K14/31 ,  C07K2319/00

摘要： A process for extending the half-life in vivo by a biologically active protein or peptide, characterized by covalently coupling said protein or peptide to a polypeptide fragment capable of binding to a serum protein, whereby when administering the resulting protein or peptide conjugate its binding to the serum protein results in extended biological activity, the use of the protein or peptide conjugate above for manufacturing a medicament which, when administered to a mammal including man, shows extended half-life in vivo; and a method of therapeutic or prophylactic treatment.

摘要翻译： 一种通过生物活性蛋白质或肽在体内延长半衰期的方法，其特征在于将所述蛋白质或肽共价偶联到能够结合血清蛋白质的多肽片段，由此当施用所得蛋白质或肽缀合物时，其结合 血清蛋白质导致延长的生物学活性，上述蛋白质或肽结合物的使用用于制备当向包括人类的哺乳动物施用时在体内显示延长的半衰期的药物; 以及治疗或预防治疗的方法。

公开(公告)号：US20140221507A1

公开(公告)日：2014-08-07

申请号：US14131212

申请日：2012-07-02

申请人： Jochen Schwenk ,  Peter Nilsson ,  Mathias Uhlén

发明人： Jochen Schwenk ,  Peter Nilsson ,  Mathias Uhlén

IPC分类号： G01N33/68

CPC分类号： G01N33/6893 ,  G01N33/493 ,  G01N2800/347

摘要： There is provided a method of determining whether a subject belongs to a first or a second group of subjects, wherein the risk of having or developing of a renal impairment is higher in the first group than in the second group, comprising the steps of: a) measuring an amount of fibulin 1 in a sample from the subject to obtain a sample value; b) comparing the sample value to a reference value; and if the sample value is higher than the reference value, c1) concluding that the subject belongs to the first group; and if the sample value is lower than the reference value, c2) concluding that the subject belongs to the second group, wherein the sample is an optionally modified sample derived from urine or blood, such as an optionally diluted serum or plasma sample. Associated means are also provided.

摘要翻译： 提供了确定受试者是否属于第一组或第二组受试者的方法，其中在第一组中具有或发展肾损伤的风险高于第二组，其包括以下步骤：a ）测量来自受试者的样品中的纤维蛋白1的量以获得样品值; b）将样本值与参考值进行比较; 并且如果样本值高于参考值，则c1）认定该受试者属于第一组; 并且如果样品值低于参考值，则c2）断定受试者属于第二组，其中样品是衍生自尿液或血液的任选修饰的样品，例如任选稀释的血清或血浆样品。 还提供了相关的手段。

公开(公告)号：US08465934B2

公开(公告)日：2013-06-18

申请号：US13542723

申请日：2012-07-06

申请人： Mathias Uhlén ,  Fredrik Pontén

发明人： Mathias Uhlén ,  Fredrik Pontén

IPC分类号： G01N33/53 ,  G01N33/574

CPC分类号： G01N33/57419 ,  G01N2333/4703

摘要： The invention provides new methods, means and uses in connection with detection, characterization and prognosis of colo-rectal cancer, via the identification of the SATB2 protein as a marker for this cancer type.

摘要翻译： 本发明通过鉴定SATB2蛋白作为该癌症类型的标志物，提供了与直肠癌的检测，表征和预后有关的新方法，手段和用途。

公开(公告)号：US06610479B1

公开(公告)日：2003-08-26

申请号：US08952570

申请日：1998-02-13

申请人： Joakim Lundeberg ,  Mathias Uhlén

发明人： Joakim Lundeberg ,  Mathias Uhlén

IPC分类号： C12Q168

CPC分类号： C12Q1/6848 ,  C07K14/315 ,  C07K14/70535 ,  C07K2319/00 ,  C12N9/1252 ,  C12Q1/686 ,  Y10S435/81 ,  C12Q2549/107 ,  C12Q2527/127

摘要： Enzymes or catalytic fragments thereof reversibly inactivated by attachment to an immobilizing moiety which may comprise a magnetic particle are activated by release from the immobilizing moiety. The enzyme or fragment may be in the form of a fusion protein that is attached to the immobilizing moiety via a pair of affinity binding partners such that the enzyme or fragment is reversibly inactivated, and release of the fusion protein from the immobilizing moiety activates the enzyme or fragment. Enzymes include DNA polymerases, DNA ligases, Reverse transcriptases and RNA polymerases. The enzyme or fragment may be thermostable, and the fusion protein can be bound to the immobilizing moiety via a heat-labile linkage. Activation of the reversibly inactivated immobilized enzyme or fragment has particular utility in PCR and analogous nucleic acid amplification techniques. A sample containing a nucleic acid is contacted with the immobilized fusion protein, and release of the fusion protein activates the enzyme or fragment to start a first cycle of an amplification reaction. Amplification reactions that may be carried out include Ligase chain reaction (LCR), Self-sustained Sequence Replication (3SR), Reverse transcriptase PCR (RT-PCR), Q-beta replicase amplification reaction and nucleic acid sequence-based amplification (NASBA). Kits for the amplifications may be prepared containing an appropriate reversibly immobilized enzyme in the form of a fusion protein, and primers and/or probe for performing the amplification.

摘要翻译： 通过与固定部分连接可逆地失活的酶或其催化片段可以由固定化部分释放而被活化。 酶或片段可以是融合蛋白的形式，其通过一对亲和结合配偶体与固定化部分连接，使得酶或片段可逆地失活，并且融合蛋白从固定化部分的释放激活酶 或片段。 酶包括DNA聚合酶，DNA连接酶，逆转录酶和RNA聚合酶。 酶或片段可以是热稳定的，并且融合蛋白可以通过热不稳定连接键与固定部分结合。 可逆灭活的固定化酶或片段的活化在PCR和类似的核酸扩增技术中具有特别的用途。 将含有核酸的样品与固定化的融合蛋白接触，并且融合蛋白的释放激活酶或片段以开始扩增反应的第一循环。 可能进行的扩增反应包括连接酶链反应（LCR），自持序列复制（3SR），逆转录酶PCR（RT-PCR），Q-β复制酶扩增反应和基于核酸序列的扩增（NASBA）。 可以制备用于扩增的试剂盒，其含有融合蛋白形式的合适的可逆固定的酶，以及用于进行扩增的引物和/或探针。

公开(公告)号：US08420788B2

公开(公告)日：2013-04-16

申请号：US13062820

申请日：2009-10-06

申请人： Karin Jirström ,  Fredrik Pontén ,  Mathias Uhlén

发明人： Karin Jirström ,  Fredrik Pontén ,  Mathias Uhlén

IPC分类号： C07K16/00

CPC分类号： C07K14/4702 ,  C07K14/4748 ,  C07K16/18 ,  C07K16/22 ,  C07K2317/34 ,  G01N33/57419 ,  G01N2800/56

摘要： The present invention relates to an affinity ligand capable of selective interaction with an epitope sequence consisting of 47 amino acids or less and comprising the amino acid sequence of SEQ ID NO:1 and/or SEQ ID NO:2. Further, it relates to a polypeptide consisting of the epitope sequence and to uses of the affinity ligand and the polypeptide.

摘要翻译： 本发明涉及能够与由47个氨基酸或更少组成的表位序列选择性相互作用并且包含SEQ ID NO：1和/或SEQ ID NO：2的氨基酸序列的亲和配体。 此外，它涉及由表位序列和亲和配体和多肽的用途组成的多肽。

公开(公告)号：US20120058202A1

公开(公告)日：2012-03-08

申请号：US13201740

申请日：2010-02-16

申请人： Mathias Uhlén ,  Fredrik Pontén ,  Karin Jirström ,  Donal J. Brennan

发明人： Mathias Uhlén ,  Fredrik Pontén ,  Karin Jirström ,  Donal J. Brennan

IPC分类号： A61K31/555 ,  C12Q1/68 ,  C40B30/04 ,  C07K16/18 ,  C07K14/47 ,  C07K7/06 ,  C07K4/12 ,  G01N33/574 ,  A61P35/00

CPC分类号： G01N33/689 ,  C07K14/4748 ,  G01N33/5743

摘要： There is provided a method for determining whether a mammalian subject having an ovarian cancer belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group, comprising the steps of: a) evaluating an amount of RBM3 protein in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount; b) comparing said sample value with a predetermined refer-ence value; and if said sample value is higher than said ref-erence value, c1) concluding that the subject belongs to the first group; and if said sample value is lower than or equal to said reference value, c2) concluding that the sub-ject belongs to the second group. Related peptides, affinity ligands, uses and further methods are also provided.

摘要翻译： 提供了一种用于确定具有卵巢癌的哺乳动物受试者是否属于第一组或第二组的方法，其中第一组受试者的预后优于第二组受试者的预后，包括以下步骤： a）评估早期从受试者获得的样品的至少一部分中的RBM3蛋白的量，并确定对应于评估量的样品值; b）将所述样本值与预定参考值进行比较; 并且如果所述样本值高于所述参考值，则c1）得出结论，所述受试者属于第一组; 并且如果所述样本值小于或等于所述参考值，则c2）推断子项目属于第二组。 还提供了相关肽，亲和配体，用途和其它方法。

公开(公告)号：US08728739B2

公开(公告)日：2014-05-20

申请号：US13210816

申请日：2011-08-16

申请人： Mathias Uhlén ,  Fredrik Pontén ,  Karin Jirström

发明人： Mathias Uhlén ,  Fredrik Pontén ,  Karin Jirström

IPC分类号： C12Q1/68 ,  G01N33/53

CPC分类号： C07K16/18 ,  A61K31/7068 ,  A61K39/39533 ,  A61K45/06 ,  C07K14/4748 ,  C07K16/3038 ,  C07K2317/34 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N33/57407 ,  G01N33/57419 ,  A61K2300/00

摘要： The present invention provides means, such as a method, for determining whether a mammalian subject having a colorectal cancer belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group. The method comprises the steps of: evaluating an amount of RBM3 protein or RBM3 mRNA molecule in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount; comparing said sample value with a predetermined reference value; andif said sample value is higher than said reference value, concluding that the subject belongs to the first group; and if said sample value is lower than or equal to said reference value, concluding that the subject belongs to the second group.

摘要翻译： 本发明提供了用于确定具有结肠直肠癌的哺乳动物受试者是否属于第一组或第二组的方法，例如方法，其中第一组受试者的预后优于第二组受试者的预后 。 该方法包括以下步骤：评估早期从受试者获得的样品的至少部分中的RBM3蛋白或RBM3 mRNA分子的量，并确定对应于评估量的样品值; 将所述样本值与预定参考值进行比较; 并且如果所述样本值高于所述参考值，则认定所述对象属于所述第一组; 并且如果所述样本值低于或等于所述参考值，则认定所述对象属于所述第二组。